Anxiety-like behavior of mice produced by conditional central expression of the HIV-1 regulatory protein, Tat
Rationale Human immunodeficiency virus (HIV) infection is associated with substantial increases in generalized anxiety. The HIV regulatory protein, transactivator of transcription (Tat), has been implicated in the neuropathogenesis related to HIV-1 infection. However, direct examination of the effec...
Gespeichert in:
Veröffentlicht in: | Psychopharmacology 2014-06, Vol.231 (11), p.2349-2360 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2360 |
---|---|
container_issue | 11 |
container_start_page | 2349 |
container_title | Psychopharmacology |
container_volume | 231 |
creator | Paris, Jason J. Singh, Harminder D. Ganno, Michelle L. Jackson, Pauline McLaughlin, Jay P. |
description | Rationale
Human immunodeficiency virus (HIV) infection is associated with substantial increases in generalized anxiety. The HIV regulatory protein, transactivator of transcription (Tat), has been implicated in the neuropathogenesis related to HIV-1 infection. However, direct examination of the effect of Tat on behavioral measures of anxiety has not been demonstrated.
Objective
To identify whether expression of the Tat
1-86
protein exerts dose-dependent and persistent anxiety-like effects in a whole animal model, the GT-tg bigenic mouse.
Methods
GT-tg mice and C57BL/6J controls were administered doxycycline in a dose- (0, 50, 100, or 125 mg/kg, i.p., for 7 days) or duration- (100 mg/kg, i.p., for 0, 1, 3, 5, or 14 days) dependent manner to induce Tat
1-86
in brain. Mice were assessed for anxiety-like behavior in an open field, social interaction, or marble burying task 0, 7, and/or 14 days later. Central expression of Tat
1-86
protein was verified with Western blot analyses.
Results
Doxycycline produced no effects on C57BL/6J controls that lacked the Tat
1-86
transgene. Among GT-tg mice, doxycycline (100 mg/kg for 3, 5, or 7 days) significantly increased anxiety-like behavior in all tasks, commensurate with enhanced Western blot labeling of Tat
1-86
protein in brain, displaying optimal effects with the 7-day regimen. Greater exposure to doxycycline (either 125 mg/kg for 7 days or 100 mg/kg for 14 days) impaired locomotor behavior; whereas lower dosing (below 100 mg/kg) produced only transient increases in anxiety-like behavior.
Conclusions
Expression of HIV-1-Tat
1-86
in GT-tg mouse brain produces exposure-dependent, persistent increases in anxiety-like behavior. |
doi_str_mv | 10.1007/s00213-013-3385-1 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4020990</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A372250933</galeid><sourcerecordid>A372250933</sourcerecordid><originalsourceid>FETCH-LOGICAL-c636t-3ceaf00a0734b2cefa0649029e68de9ede5275a4b884fdbe12541ac76e8103193</originalsourceid><addsrcrecordid>eNp1Uk1v1DAQtRCILoUfwAVZ4tIDKeOvfFyQVhW0lSpxKVwtx5nsumTtxU6q7r_HYbelRWDLGmnmvWfP-BHylsEpA6g-JgDORAH5CFGrgj0jCyYFLzhU_DlZAIhcYao-Iq9SuoG8ZC1fkiMuheKqrBdks_R3DsddMbgfSFtcm1sXIg093TiLdBtDN1nsaLujNvjOjS54M1CLfow54t02Yko5OVPGNdKLy-8FoxFX02DGEHezxIjOf6DXZnxNXvRmSPjmEI_Jty-fr88uiquv55dny6vClqIcC2HR9AAGKiFbbrE3UMoGeINl3WGDHSpeKSPbupZ91yLjSjJjqxJrBoI14ph82utup3aD3eG1ehvdxsSdDsbppxXv1noVbrUEDk0DWeDkIBDDzwnTqDcuWRwG4zFMSTPFm0bIUlQZ-v4v6E2YYh7Sb5TkUqm6-YNamQG1833I99pZVC9FxbmCRoiMOv0HKu8O83cEj73L-ScEtifYGFKK2D_0yEDPHtF7j-jsET17RLPMefd4OA-Me1NkAN8DUi75FcZHHf1X9ReBNcZa</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1524245589</pqid></control><display><type>article</type><title>Anxiety-like behavior of mice produced by conditional central expression of the HIV-1 regulatory protein, Tat</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Paris, Jason J. ; Singh, Harminder D. ; Ganno, Michelle L. ; Jackson, Pauline ; McLaughlin, Jay P.</creator><creatorcontrib>Paris, Jason J. ; Singh, Harminder D. ; Ganno, Michelle L. ; Jackson, Pauline ; McLaughlin, Jay P.</creatorcontrib><description>Rationale
Human immunodeficiency virus (HIV) infection is associated with substantial increases in generalized anxiety. The HIV regulatory protein, transactivator of transcription (Tat), has been implicated in the neuropathogenesis related to HIV-1 infection. However, direct examination of the effect of Tat on behavioral measures of anxiety has not been demonstrated.
Objective
To identify whether expression of the Tat
1-86
protein exerts dose-dependent and persistent anxiety-like effects in a whole animal model, the GT-tg bigenic mouse.
Methods
GT-tg mice and C57BL/6J controls were administered doxycycline in a dose- (0, 50, 100, or 125 mg/kg, i.p., for 7 days) or duration- (100 mg/kg, i.p., for 0, 1, 3, 5, or 14 days) dependent manner to induce Tat
1-86
in brain. Mice were assessed for anxiety-like behavior in an open field, social interaction, or marble burying task 0, 7, and/or 14 days later. Central expression of Tat
1-86
protein was verified with Western blot analyses.
Results
Doxycycline produced no effects on C57BL/6J controls that lacked the Tat
1-86
transgene. Among GT-tg mice, doxycycline (100 mg/kg for 3, 5, or 7 days) significantly increased anxiety-like behavior in all tasks, commensurate with enhanced Western blot labeling of Tat
1-86
protein in brain, displaying optimal effects with the 7-day regimen. Greater exposure to doxycycline (either 125 mg/kg for 7 days or 100 mg/kg for 14 days) impaired locomotor behavior; whereas lower dosing (below 100 mg/kg) produced only transient increases in anxiety-like behavior.
Conclusions
Expression of HIV-1-Tat
1-86
in GT-tg mouse brain produces exposure-dependent, persistent increases in anxiety-like behavior.</description><identifier>ISSN: 0033-3158</identifier><identifier>EISSN: 1432-2072</identifier><identifier>DOI: 10.1007/s00213-013-3385-1</identifier><identifier>PMID: 24352568</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Animal behavior ; Animals ; Anxiety ; Anxiety Disorders - chemically induced ; Anxiety Disorders - physiopathology ; Biomedical and Life Sciences ; Biomedicine ; Blotting, Western ; Brain ; Brain - drug effects ; Brain - physiopathology ; Complications and side effects ; Development and progression ; Dose-Response Relationship, Drug ; Doxycycline - pharmacology ; Gene Expression - drug effects ; Genetic aspects ; HIV ; HIV infection ; Human immunodeficiency virus ; Human immunodeficiency virus 1 ; Male ; Mice, Inbred C57BL ; Mice, Transgenic ; Neuropsychological Tests ; Neurosciences ; Original Investigation ; Pharmacology/Toxicology ; Physiological aspects ; Proteins ; Psychiatry ; Psychological aspects ; Psychotropic Drugs - pharmacology ; Risk factors ; Rodents ; tat Gene Products, Human Immunodeficiency Virus - genetics ; tat Gene Products, Human Immunodeficiency Virus - metabolism ; Time Factors ; Viral proteins</subject><ispartof>Psychopharmacology, 2014-06, Vol.231 (11), p.2349-2360</ispartof><rights>Springer-Verlag Berlin Heidelberg 2013</rights><rights>COPYRIGHT 2014 Springer</rights><rights>Springer-Verlag Berlin Heidelberg 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c636t-3ceaf00a0734b2cefa0649029e68de9ede5275a4b884fdbe12541ac76e8103193</citedby><cites>FETCH-LOGICAL-c636t-3ceaf00a0734b2cefa0649029e68de9ede5275a4b884fdbe12541ac76e8103193</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00213-013-3385-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00213-013-3385-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,780,784,885,27922,27923,41486,42555,51317</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24352568$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Paris, Jason J.</creatorcontrib><creatorcontrib>Singh, Harminder D.</creatorcontrib><creatorcontrib>Ganno, Michelle L.</creatorcontrib><creatorcontrib>Jackson, Pauline</creatorcontrib><creatorcontrib>McLaughlin, Jay P.</creatorcontrib><title>Anxiety-like behavior of mice produced by conditional central expression of the HIV-1 regulatory protein, Tat</title><title>Psychopharmacology</title><addtitle>Psychopharmacology</addtitle><addtitle>Psychopharmacology (Berl)</addtitle><description>Rationale
Human immunodeficiency virus (HIV) infection is associated with substantial increases in generalized anxiety. The HIV regulatory protein, transactivator of transcription (Tat), has been implicated in the neuropathogenesis related to HIV-1 infection. However, direct examination of the effect of Tat on behavioral measures of anxiety has not been demonstrated.
Objective
To identify whether expression of the Tat
1-86
protein exerts dose-dependent and persistent anxiety-like effects in a whole animal model, the GT-tg bigenic mouse.
Methods
GT-tg mice and C57BL/6J controls were administered doxycycline in a dose- (0, 50, 100, or 125 mg/kg, i.p., for 7 days) or duration- (100 mg/kg, i.p., for 0, 1, 3, 5, or 14 days) dependent manner to induce Tat
1-86
in brain. Mice were assessed for anxiety-like behavior in an open field, social interaction, or marble burying task 0, 7, and/or 14 days later. Central expression of Tat
1-86
protein was verified with Western blot analyses.
Results
Doxycycline produced no effects on C57BL/6J controls that lacked the Tat
1-86
transgene. Among GT-tg mice, doxycycline (100 mg/kg for 3, 5, or 7 days) significantly increased anxiety-like behavior in all tasks, commensurate with enhanced Western blot labeling of Tat
1-86
protein in brain, displaying optimal effects with the 7-day regimen. Greater exposure to doxycycline (either 125 mg/kg for 7 days or 100 mg/kg for 14 days) impaired locomotor behavior; whereas lower dosing (below 100 mg/kg) produced only transient increases in anxiety-like behavior.
Conclusions
Expression of HIV-1-Tat
1-86
in GT-tg mouse brain produces exposure-dependent, persistent increases in anxiety-like behavior.</description><subject>Animal behavior</subject><subject>Animals</subject><subject>Anxiety</subject><subject>Anxiety Disorders - chemically induced</subject><subject>Anxiety Disorders - physiopathology</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Blotting, Western</subject><subject>Brain</subject><subject>Brain - drug effects</subject><subject>Brain - physiopathology</subject><subject>Complications and side effects</subject><subject>Development and progression</subject><subject>Dose-Response Relationship, Drug</subject><subject>Doxycycline - pharmacology</subject><subject>Gene Expression - drug effects</subject><subject>Genetic aspects</subject><subject>HIV</subject><subject>HIV infection</subject><subject>Human immunodeficiency virus</subject><subject>Human immunodeficiency virus 1</subject><subject>Male</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Transgenic</subject><subject>Neuropsychological Tests</subject><subject>Neurosciences</subject><subject>Original Investigation</subject><subject>Pharmacology/Toxicology</subject><subject>Physiological aspects</subject><subject>Proteins</subject><subject>Psychiatry</subject><subject>Psychological aspects</subject><subject>Psychotropic Drugs - pharmacology</subject><subject>Risk factors</subject><subject>Rodents</subject><subject>tat Gene Products, Human Immunodeficiency Virus - genetics</subject><subject>tat Gene Products, Human Immunodeficiency Virus - metabolism</subject><subject>Time Factors</subject><subject>Viral proteins</subject><issn>0033-3158</issn><issn>1432-2072</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1Uk1v1DAQtRCILoUfwAVZ4tIDKeOvfFyQVhW0lSpxKVwtx5nsumTtxU6q7r_HYbelRWDLGmnmvWfP-BHylsEpA6g-JgDORAH5CFGrgj0jCyYFLzhU_DlZAIhcYao-Iq9SuoG8ZC1fkiMuheKqrBdks_R3DsddMbgfSFtcm1sXIg093TiLdBtDN1nsaLujNvjOjS54M1CLfow54t02Yko5OVPGNdKLy-8FoxFX02DGEHezxIjOf6DXZnxNXvRmSPjmEI_Jty-fr88uiquv55dny6vClqIcC2HR9AAGKiFbbrE3UMoGeINl3WGDHSpeKSPbupZ91yLjSjJjqxJrBoI14ph82utup3aD3eG1ehvdxsSdDsbppxXv1noVbrUEDk0DWeDkIBDDzwnTqDcuWRwG4zFMSTPFm0bIUlQZ-v4v6E2YYh7Sb5TkUqm6-YNamQG1833I99pZVC9FxbmCRoiMOv0HKu8O83cEj73L-ScEtifYGFKK2D_0yEDPHtF7j-jsET17RLPMefd4OA-Me1NkAN8DUi75FcZHHf1X9ReBNcZa</recordid><startdate>20140601</startdate><enddate>20140601</enddate><creator>Paris, Jason J.</creator><creator>Singh, Harminder D.</creator><creator>Ganno, Michelle L.</creator><creator>Jackson, Pauline</creator><creator>McLaughlin, Jay P.</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QR</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7U9</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20140601</creationdate><title>Anxiety-like behavior of mice produced by conditional central expression of the HIV-1 regulatory protein, Tat</title><author>Paris, Jason J. ; Singh, Harminder D. ; Ganno, Michelle L. ; Jackson, Pauline ; McLaughlin, Jay P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c636t-3ceaf00a0734b2cefa0649029e68de9ede5275a4b884fdbe12541ac76e8103193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animal behavior</topic><topic>Animals</topic><topic>Anxiety</topic><topic>Anxiety Disorders - chemically induced</topic><topic>Anxiety Disorders - physiopathology</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Blotting, Western</topic><topic>Brain</topic><topic>Brain - drug effects</topic><topic>Brain - physiopathology</topic><topic>Complications and side effects</topic><topic>Development and progression</topic><topic>Dose-Response Relationship, Drug</topic><topic>Doxycycline - pharmacology</topic><topic>Gene Expression - drug effects</topic><topic>Genetic aspects</topic><topic>HIV</topic><topic>HIV infection</topic><topic>Human immunodeficiency virus</topic><topic>Human immunodeficiency virus 1</topic><topic>Male</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Transgenic</topic><topic>Neuropsychological Tests</topic><topic>Neurosciences</topic><topic>Original Investigation</topic><topic>Pharmacology/Toxicology</topic><topic>Physiological aspects</topic><topic>Proteins</topic><topic>Psychiatry</topic><topic>Psychological aspects</topic><topic>Psychotropic Drugs - pharmacology</topic><topic>Risk factors</topic><topic>Rodents</topic><topic>tat Gene Products, Human Immunodeficiency Virus - genetics</topic><topic>tat Gene Products, Human Immunodeficiency Virus - metabolism</topic><topic>Time Factors</topic><topic>Viral proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Paris, Jason J.</creatorcontrib><creatorcontrib>Singh, Harminder D.</creatorcontrib><creatorcontrib>Ganno, Michelle L.</creatorcontrib><creatorcontrib>Jackson, Pauline</creatorcontrib><creatorcontrib>McLaughlin, Jay P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Paris, Jason J.</au><au>Singh, Harminder D.</au><au>Ganno, Michelle L.</au><au>Jackson, Pauline</au><au>McLaughlin, Jay P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anxiety-like behavior of mice produced by conditional central expression of the HIV-1 regulatory protein, Tat</atitle><jtitle>Psychopharmacology</jtitle><stitle>Psychopharmacology</stitle><addtitle>Psychopharmacology (Berl)</addtitle><date>2014-06-01</date><risdate>2014</risdate><volume>231</volume><issue>11</issue><spage>2349</spage><epage>2360</epage><pages>2349-2360</pages><issn>0033-3158</issn><eissn>1432-2072</eissn><abstract>Rationale
Human immunodeficiency virus (HIV) infection is associated with substantial increases in generalized anxiety. The HIV regulatory protein, transactivator of transcription (Tat), has been implicated in the neuropathogenesis related to HIV-1 infection. However, direct examination of the effect of Tat on behavioral measures of anxiety has not been demonstrated.
Objective
To identify whether expression of the Tat
1-86
protein exerts dose-dependent and persistent anxiety-like effects in a whole animal model, the GT-tg bigenic mouse.
Methods
GT-tg mice and C57BL/6J controls were administered doxycycline in a dose- (0, 50, 100, or 125 mg/kg, i.p., for 7 days) or duration- (100 mg/kg, i.p., for 0, 1, 3, 5, or 14 days) dependent manner to induce Tat
1-86
in brain. Mice were assessed for anxiety-like behavior in an open field, social interaction, or marble burying task 0, 7, and/or 14 days later. Central expression of Tat
1-86
protein was verified with Western blot analyses.
Results
Doxycycline produced no effects on C57BL/6J controls that lacked the Tat
1-86
transgene. Among GT-tg mice, doxycycline (100 mg/kg for 3, 5, or 7 days) significantly increased anxiety-like behavior in all tasks, commensurate with enhanced Western blot labeling of Tat
1-86
protein in brain, displaying optimal effects with the 7-day regimen. Greater exposure to doxycycline (either 125 mg/kg for 7 days or 100 mg/kg for 14 days) impaired locomotor behavior; whereas lower dosing (below 100 mg/kg) produced only transient increases in anxiety-like behavior.
Conclusions
Expression of HIV-1-Tat
1-86
in GT-tg mouse brain produces exposure-dependent, persistent increases in anxiety-like behavior.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>24352568</pmid><doi>10.1007/s00213-013-3385-1</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0033-3158 |
ispartof | Psychopharmacology, 2014-06, Vol.231 (11), p.2349-2360 |
issn | 0033-3158 1432-2072 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4020990 |
source | MEDLINE; SpringerLink Journals - AutoHoldings |
subjects | Animal behavior Animals Anxiety Anxiety Disorders - chemically induced Anxiety Disorders - physiopathology Biomedical and Life Sciences Biomedicine Blotting, Western Brain Brain - drug effects Brain - physiopathology Complications and side effects Development and progression Dose-Response Relationship, Drug Doxycycline - pharmacology Gene Expression - drug effects Genetic aspects HIV HIV infection Human immunodeficiency virus Human immunodeficiency virus 1 Male Mice, Inbred C57BL Mice, Transgenic Neuropsychological Tests Neurosciences Original Investigation Pharmacology/Toxicology Physiological aspects Proteins Psychiatry Psychological aspects Psychotropic Drugs - pharmacology Risk factors Rodents tat Gene Products, Human Immunodeficiency Virus - genetics tat Gene Products, Human Immunodeficiency Virus - metabolism Time Factors Viral proteins |
title | Anxiety-like behavior of mice produced by conditional central expression of the HIV-1 regulatory protein, Tat |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T15%3A40%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anxiety-like%20behavior%20of%20mice%20produced%20by%20conditional%20central%20expression%20of%20the%20HIV-1%20regulatory%20protein,%20Tat&rft.jtitle=Psychopharmacology&rft.au=Paris,%20Jason%20J.&rft.date=2014-06-01&rft.volume=231&rft.issue=11&rft.spage=2349&rft.epage=2360&rft.pages=2349-2360&rft.issn=0033-3158&rft.eissn=1432-2072&rft_id=info:doi/10.1007/s00213-013-3385-1&rft_dat=%3Cgale_pubme%3EA372250933%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1524245589&rft_id=info:pmid/24352568&rft_galeid=A372250933&rfr_iscdi=true |